Chemical validation of GPI biosynthesis as a drug target against African sleeping sickness.
It has been suggested that compounds affecting glycosylphosphatidylinositol (GPI) biosynthesis in bloodstream form Trypanosoma brucei should be trypanocidal. We describe cell-permeable analogues of a GPI intermediate that are toxic to this parasite but not to human cells. These analogues are metabolized by the T. brucei GPI pathway, but not by the human pathway. Closely related nonmetabolizable analogues have no trypanocidal activity. This represents the first direct chemical validation of the GPI biosynthetic pathway as a drug target against African human sleeping sickness. The results should stimulate further inhibitor design and synthesis and encourage the search for inhibitors in natural product and synthetic compound libraries.
Smith
Terry K
TK
Division of Biological Chemistry and Molecular Microbiology, The Wellcome Trust Biocentre, School of Life Sciences, University of Dundee, Dundee, Scotland, UK.
Crossman
Arthur
A
Brimacombe
John S
JS
Ferguson
Michael A J
MA
D000818:Animals; D002463:Cell Membrane Permeability; D017261:Glycosylphosphatidylinositols / Q000037:antagonists & inhibitors* / Q000138:chemical synthesis* / Q000378:metabolism / Q000494:pharmacology; D006367:HeLa Cells; D006801:Humans; D014344:Trypanocidal Agents / Q000138:chemical synthesis* / Q000378:metabolism / Q000494:pharmacology; D014346:Trypanosoma brucei brucei / Q000187:drug effects* / Q000378:metabolism; D014353:Trypanosomiasis, African / Q000188:drug therapy
D017261:Glycosylphosphatidylinositols; D014344:Trypanocidal Agents